These data earned sebelipase alfa a place on this year's Honours List. In terms of adverse effects, it frequently provokes hypersensitivity reactions and occasionally anaphylactic reactions. In this situation, sebelipase alfa (Kanuma°) appears to prolong the survival of some infants by several years at least, and their childhood development is satisfactory. Infants under the age of 6 months with a symptomatic form of lysosomal acid lipase deficiency generally die during the first year of life. Sebelipase alfa: extends survival, but long-term data are lacking The wider availability of a life-saving drug is a welcome development, even though it took decades to materialise. For this reason, Prenoxad° was only rated as "Noteworthy". However, flaws in this product's packaging could result in needlestick injuries or injection of all five doses contained in the syringe in one go. The availability of Prenoxad° for opioid users is also a therapeutic advance, because the intramuscular route is a useful option when the nasal route cannot be used, for example in the event of nasal congestion. Nalscue° has thus earned a place on the 2018 Honours List. Nasal administration appears straightforward. It has been shown in the real-world setting that when naloxone is made available, nasal administration in cases of opioid overdose has similar efficacy to intramuscular administration. Both products are authorised for administration by the person who has taken an opioid overdose, by relatives or friends. In 2018, two new products containing naloxone became available in France: Nalscue°, for nasal administration and Prenoxad°, a kit containing a pre-filled syringe for intramuscular injection. Naloxone has been available in France for several decades as an injectable solution, in ampoules, but was only authorised for use by health professionals. Naloxone is the first-choice antidote after an opioid overdose: it effectively prevents death through respiratory depression in this situation. Naloxone: wider availability of a life-saving drugĪll opioid receptor agonists carry a risk of overdose, irrespective of the situation in which they are taken. Nevertheless, five drugs received a Prescrire Drug Award for 2018: two that earned a place on the Honours List and three that were deemed "Noteworthy" (see above). These awards honour drugs that constitute a therapeutic advance, in that they offer better efficacy, less frequent or less severe adverse effects (for similar efficacy), or safer or easier administration of a drug with a favourable harm-benefit balance.įive Prescrire Drug Awards for 2018, but no Pilule d'Orįor the fourth year running, none of the drugs examined in 2018 offered a therapeutic advance worthy of a Pilule d'Or (Golden Pill Awards). The Prescrire Drug Awards are determined at the end of each year, based on the reviews published that year in our French edition, and taking into account any new data made available since the initial articles were published. Our independence is made possible by the fact that we are financed exclusively by our subscribers, carry no paid advertising in either the French or the English edition, and receive no grants or subsidies of any kind. The Prescrire Editorial Staff conduct these analyses free from any industry or institutional influence. Our analyses are based on rigorous procedures, described in detail at. The goal is to help readers distinguish, among the plethora of new products, those worth adding to their list of useful therapies, those worth using instead of other products, and those to be avoided. PRENOXAD° (naloxone kit for IM injection)Įmergency treatment of opioid overdose at home or in other non-medical settings (Rev Prescrire n° 417)Īcute promyelocytic leukaemia at low or intermediate risk of relapse, in combination with tretinoin (Prescrire Int n° 193))Įach month, the Prescrire Editorial Staff publish systematic analyses of the data available on: new drugs, new indications authorised for existing drugs, and existing drugs marketed in a new form or with different dose strengths.Primary premature ejaculation (Prescrire Int n° 197) Lysosomal acid lipase deficiency, in infants under the age of 6 monthsĮmergency treatment of opioid overdose at home or in other non-medical settings (Prescrire Int n° 199)ĭrugs deemed "Noteworthy" provide a modest improvement in patient care. The Pilule d'Or (Golden Pill) is granted to drugs that constitute a major therapeutic advance in a field in which no treatment was previously availableĭrugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.
0 Comments
Leave a Reply. |